Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia, has shown its efficacy in late-stage trials.
Positive Phase III results from two trials are to be presented on fitusiran at the upcoming American Society of Hematology (ASH) meeting.
Development of the drug has been far from plain sailing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze